Toward future therapies in progressive supranuclear palsy

Movement Disorders

Volumn 20, Issue SUPPL. 12, 2005, Pages

  Burn, David J ^a   Warren, Naomi M ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Progressive supranuclear palsy; Steele Richardson Olszewski syndrome; Treatment; Trophic factors

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ADVANCED GLYCATION END PRODUCT; AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BIPERIDEN; BOTULINUM TOXIN A; COCARELDOPA; DONEPEZIL; DOPAMINE DERIVATIVE; EFAROXAN; FLUOXETINE; IDAZOXAN; LEVODOPA; LISURIDE; LITHIUM; METHYSERGIDE; MIANSERIN; NORTRIPTYLINE; PERGOLIDE; PHYSOSTIGMINE; PRAMIPEXOLE; SELEGILINE; SEROTONIN; TAU PROTEIN; UNCLASSIFIED DRUG; ZOLPIDEM;

ANTICHOLINERGIC EFFECT; APRAXIA; BEHAVIOR DISORDER; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIET THERAPY; DROWSINESS; DRUG RECEPTOR BINDING; DYSKINESIA; DYSPHAGIA; DYSTONIA; ELECTROCONVULSIVE THERAPY; EYELID DISEASE; EYELID MOVEMENT; FACE MUSCLE; FUTUROLOGY; HUMAN; MOOD DISORDER; NONHUMAN; OPHTHALMOPLEGIA; PATIENT CARE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SPECTACLES; SPEECH THERAPY; TREATMENT PLANNING; VISUAL HALLUCINATION; WALKING AID;

ADRENERGIC AGENTS; ANTI-DYSKINESIA AGENTS; CHOLINERGIC AGENTS; DOPAMINE AGENTS; HUMANS; NEUROTRANSMITTER AGENTS; PALLIATIVE CARE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 13544263964     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20546     Document Type: Review

References (71)

1. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurology 2002;1:359-369.
2. Goetz CG, Leurgans S, Lang AE, Litvan I. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 2003;60:917-922.
3. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-1775.
4. Nath U, Ben-Shlomo Y, Thomson R, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124:1438-1449.
5. Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging 2001;18: 913-925.
6. Uttl B, Santacruz P, Litvan I, Grafman J. Caregiving in progressive supranuclear palsy. Neurology 1998;51:1303-1309.
7. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615-620.
8. Krack P, Marion MH. "Apraxia of lid opening", a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994;9:610-615.
9. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60:910-916.
10. Sosner J, Wall GC, Szrajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil 1993;74:537-539.
11. Suteerawattananon M, MacNeill B, Protas EJ. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy. Phys Ther 2002;82:485-495.
12. Zermansky AJ, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Anxiety and depression in PSP: common but unrelated to disease severity. Mov Disord 2002;17(Suppl. 5):S247.
13. Aarsland D, Litvan I, Salmon D, Galakso D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.
14. Tamai S, Almeida OP. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J Am Geriatr Soc 1997;45: 1033-1034.
15. Rohs G. Progressive supranuclear palsy: managing the disabilities and providing nursing support. Axone 1996;17:60-65.
16. Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001;21:41-48.
17. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in sixteen patients. Ann Neurol 1983;13:273-278.
18. Jankovic J. Progressive supranuclear palsy: clinical and pharmacological update. Neurol Clin 1984;2:473-486.
19. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36:1005-1008.
20. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338-346.
21. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-1102.
22. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255-1264.
23. Kobari M, Fukuuchi Y, Shinohara T, Nogawa S, Takahashi K. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease. Arch Neurol 1992;49:725-730.
24. D'Costa DF, Abbott RJ, Pye IF, Millac PAH. The apomorphine test in Parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991;54:870-872.
25. Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A. Apomorphine test in de novo Parkinson's disease. Funct Neurol 1992;7:295-298.
26. Litvan I, Chase TN. Traditional and experimental therapeutic approaches. In: Litvan I, editor. Progressive supranuclear palsy: clinical and research approaches. New York: Oxford University Press; 1992. p 254-269.
27. Golbe LI, Sage JI, Duvoisin RC. Drug treatment of 83 patients with progressive supranuclear palsy. Neurology 1990;40:438.
28. Tan EK, Chan LL, Wong MC. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 2003;105:132-134.
29. Kim JM, Lee KH, Choi YL, Choe GY, Jeon BS. Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy. Mov Disord 2002;17:1089-1090.
30. Defazio G, De Mari M, De Salvia R, Lamberd P, Giorelli M, Livrea. P. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Clin Neuropharmacol 1999; 22:292-294.
31. Perkin GD, Lees AJ, Stern GM, Kocen RS. Problems in the diagnosis of progressive supranuclear palsy. Can J Neurol Sci 1978;5:167-173.
32. Williams AC, Nutt J, Lake CR, et al. Actions of bromocriptine in the Shy-Drager and Steele-Richardson-Olszewksi syndromes. In: Fuxe K, Calne DB, editors. Dopaminergic ergot derivatives and motor function. Oxford: Pergamon Press; 1979. p 271-283.
33. Neophytides A, Lieberman AN, Goldstein M, et al. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1982;45:261-263.
34. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999;52:873-874.
35. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57:467-473.
36. Litvan I, Blesa R, Clark K, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36:55-61.
37. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989;26:404-407.
38. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990;47:1346-1350.
39. Frattali CM, Sonies BC, Chi-Fishman G, Litvan I. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia 1999;14:165-168.
40. Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 1991;54:832-835.
41. Blin J, Mazetti P, Mazoyer B, et al. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 1995;118:1485-1495.
42. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989;39:257-261.
43. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001; 103:123-125.
44. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41:986-991.
45. Rascol O, Sieradzan K, Peyro-Saint-Paul H, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998;13:673-676.
46. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985;35:1189-1193.
47. Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44:1072-1074.
48. Levy R, Ruberg M, Herrero MT, et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology 1995;45:127-134.
49. Foster NL, Minoshima S, Johanns J, et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000;54:1768-1773.
50. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999;341:543-544.
51. Mayr BJ, Bonelli RM, Niederwieser G, Koltringer P, Reisecker F. Zolpidem in progressive supranuclear palsy. Eur J Neurol 2002;9: 184-185.
52. Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994;35:237-239.
53. Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil 1997;78:525-529.
54. Muller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002;249:300-304.
55. Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996;46:1284-1286.
56. Netzel PJ, Sutor B. Electroconvulsive therapy-responsive depression in a patient with progressive supranuclear palsy. J ECT 2001;17:68-70.
57. Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 1994;9: 467-469.
58. Sandyk R. Transcranial AC pulsed applications of weak electromagnetic fields reduces freezing and falling in progressive supranuclear palsy: a case report. Int J Neurosci 1998;94:41-54.
59. Koller WC, Morantz R, Vetere-Overfield B, Waxman M. Autologous adrenal medullary transplant in progressive supranuclear palsy. Neurology 1989;39:1066-1068.
60. Ward-Smith PA, Berry P. Autologous transplantation as a treatment for progressive supranuclear palsy. J Neurosci Nurs 1990; 22:100-103.
61. Caparros-Lefebvre D, Elbaz A, and the Caribbean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Lancet 1999;354:281-286.
62. Lannuzel A, Michel PP, Caparros-Lefebvre D, Abaul J, Hocquemiller R, Ruberg M. Toxicity of annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov Disord 2002;17:84-90.
63. Golbe LI. Progressive supranuclear palsy in the molecular age. Lancet 2000;356:870-871.
64. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000;25:402-405.
65. Wittman CW, Wszolek MF, Shulman JM, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001;293:711-714.
66. Tomasiewicz HG, Flaherty DB, Soria JP, Wood JG. Transgenic zebrafish model of neurodegeneration. J Neurosci Res 2002;70: 734-745.
67. Mudher A, Shepherd D, Newman TA, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 2004;9:522-530.
68. Davidson BL, Paulson HL. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 2004;3:145-149.
69. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998;153:1149-1155.
70. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 2003;62:173-184.
71. Hartzler AW, Zhu X, Siedlak SL, et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiol Aging 2002;23:855-859.